ROBERT JAY HOPKINS
- Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adultsRobert J Hopkins
Emergent BioSolutions Inc, 400 Professional Drive, Gaithersburg, MD 20879, USA Electronic address
Vaccine 34:2096-105. 2016....
- Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adultsRobert J Hopkins
Clinical Development, Emergent BioSolutions, Gaithersburg, MD, USA Electronic address
Vaccine 32:2217-24. 2014..This study was conducted to support licensure of a post-exposure prophylaxis indication for BioThrax(®) (anthrax vaccine adsorbed) concurrent with antimicrobials for individuals exposed to aerosolized anthrax spores...
- Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteersRobert J Hopkins
Emergent BioSolutions Inc, Gaithersburg, MD, USA
Vaccine 31:3051-8. 2013..No AEs of special interest (autoimmune events) were observed in the study. Further studies of doses and dosing regimens are planned to assess the immunogenicity and reactogenicity of AV7909...
- Anthrax Immune Globulin to Prevent & Treat Anthrax: Clinical DevelopmentRobert Hopkins; Fiscal Year: 2006..More information about Emergent BioSolutions and its subsidiaries can be found at www.ebsi.com. [unreadable] [unreadable] [unreadable]..
- BioThrax Schedule Optimization for Post-Exposure Prophylaxis of AnthraxRobert Hopkins; Fiscal Year: 2006..unreadable] [unreadable] [unreadable]..